Effect of a new de-N-acetyl-lysoglycosphingolipid on some tumour models

Ezio Tubaro, Giorgio P. Borelli, Luisella Belogi, Giovanni Cavallo, Angela Santoni, Fabrizio Mainiero

Research output: Contribution to journalArticle

Abstract

A new de-N-acetylated glycosphingolipid termed WILD20, a breakdown product of GM1 obtained through alkaline hydrolysis, and characterized by nuclear magnetic resonance, mass spectrometry and elementary analysis, was found to inhibit phospholipase A2 via phosphokinase C translocation blockade. The substance inhibited various tumour cell lines in vitro, in synergy with doxorubicin and cisplatin. In vivo, it showed an antitumoral effect when both the tumour cells and WILD20 were injected at the same site (peritoneal cavity). Tumour cells, incubated with WILD20, showed a dose-dependent decrease of oncogenicity without impairment of viability. WILD20 also down-regulated tumour cell adherence to laminin and fibronectin. When peritumorally administered, WILD20 impaired tumour growth and potentiated the peritumoral effects of recombinant interleukin 2. The results obtained merit exploration of the therapeutical possibilities of this agent in human cancer patients.

Original languageEnglish
Pages (from-to)555-563
Number of pages9
JournalEuropean Journal of Pharmacology
Volume294
Issue number2-3
DOIs
Publication statusPublished - Dec 29 1995

Keywords

  • Adhesion
  • Glycosphingolipid
  • Peritumoral
  • Recombinant interleukin-2
  • Tumor

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Effect of a new de-N-acetyl-lysoglycosphingolipid on some tumour models'. Together they form a unique fingerprint.

  • Cite this

    Tubaro, E., Borelli, G. P., Belogi, L., Cavallo, G., Santoni, A., & Mainiero, F. (1995). Effect of a new de-N-acetyl-lysoglycosphingolipid on some tumour models. European Journal of Pharmacology, 294(2-3), 555-563. https://doi.org/10.1016/0014-2999(95)00583-8